Investors

Investor Relations

Akebia Therapeutics

Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization.

We have a portfolio focused on addressing significant unmet needs for people living with kidney disease.

OUR MEDICINE

RESEARCH & DEVELOPMENT

Press Releases

December 18, 2024

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 3, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 3, 2024

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

VIEW ALL PRESS RELEASES

Events & Presentations

January 16, 2025 at 7:30 AM PST

43rd Annual J.P. Morgan Healthcare Conference

December 3, 2024 at 10:30 AM EST

Piper Sandler 36th Annual Healthcare Conference

November 21, 2024 at 1:00 PM GMT

Jefferies London Healthcare Conference

VIEW ALL EVENTS

Data Presentations

Presented at ASN Kidney Week 2021

Comprehensive Safety Profile of Vadadustat from Global Phase 3 Clinical Trials

Presented at ASN Kidney Week 2021

Vadadustat for Treatment of Anemia in Patients with Dialysis-Dependent CKD Receiving Peritoneal Dialysis

Presented at ASN Kidney Week 2021

Vadadustat, an Oral HIF-PHI, Is Not Associated with Increased Risk of Neoplasm in Patients with Anemia Due to CKD

VIEW ALL DATA PRESENTATIONS

Volume:

Today’s Open:

Previous Close:

Print Page

Email Page

Contact IR

Email Alerts

Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098 phone
+1 617.871.2099 fax